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Summary 
Despite repeated exposure to HIV-1, certain individuals remain persistently uninfected. Such 
exposed uninfected (EU) people show evidence of HIV-l-specific T  cell immunity and, in 
rare cases, selective resistance to infection by macrophage-tropic strains  of HIV-1.  The latter 
has been associated with a 32-base pair deletion in the C-C chemokine receptor gene CCR-5, 
the major coreceptor of macrophage-tropic strains  of HIV-1. We have undertaken an analysis 
of the HIV-specific T  cell responses in 12 EU individuals who were either homozygous for the 
wild-type CCR-5 allele or heterozygous for the deletion allele (CCR-5A32). We have found 
evidence of an oligoclonal T  cell response mediated by helper T  cells specific for a conserved 
region of the HIV-1 envelope. These cells produce very high levels ofC-C chemokines when 
stimulated by the specific antigen and suppress  selectively the replication ofmacrophage-tropic, 
but not T  cell-tropic, strains  of HIV-1. These chemokine-producing helper cells may be part 
of a protective immune response that could be potentially exploited for vaccine development. 
M  any individuals  who  remain persistently uninfected 
despite repeated exposure to HIV display evidence of 
HIV-specific immunity, including antigen-driven T  helper 
cell-mediated cytokine production (1-3)  and cytotoxicity 
induced by HIV early proteins (4-6). This implies that in 
some cases chronic exposure to HIV may lead to protective 
immunity rather than infection. A well-characterized path- 
way of HIV suppression involves CD8  T  cells producing 
C-C chemokines (7). Evidence for the in vivo relevance of 
such a pathway comes from the observation that rare individ- 
uals homozygous for a deletion within the C-C chemokine 
receptor gene CCR-5  (CCR-5A32) are resistant to HIV-1 
infection (8,  9),  although infection in  a  CCR-5A32  ho- 
mozygous individual has also been reported (10). CCP,.-5 is 
the major coreceptor ofmacrophage-tropic nonsyncytium- 
inducing (NSI) strains  of HIV-1  (11-14), which are con- 
sidered to be preferentially involved in sexual transmission 
and  constitute  the  predominant  phenotype in  newly in- 
fected individuals.  T  cell-tropic syncytium-inducing  (SI) 
strains appear later in infection (15). It is estimated that CCR- 
5A32 homozygosity is present in 1% of the Caucasian pop- 
ulation  (8).  In  high  risk  groups,  the  frequency is  only 
slightly elevated (2.8%)  (16); thus, the CCR-5A32 deletion 
does not fully account for HIV resistance.  Other mecha- 
nisms of resistance to infection may involve other muta- 
tions in the CCR-5 gene or in genes coding for alternative 
coreceptors. On the other hand, specific immune responses 
induced by exposure to HIV antigens may prevent infec- 
tion by interfering with the  same pathway of HIV entry. 
Such immune responses may play a role in CC1L-5 wild- 
type homozygous exposed uninfected (EU) individuals whose 
cells  are  fully competent to  support the  growth  of mac- 
rophage-tropic  strains  of HIV-1  (12).  Specific immunity 
may be driven by cytotoxic as well as helper T  cells pro- 
ducing C--C chemokines. Indeed, CD4 + T  cells from EU 
individuals  have  been  shown  to produce high levels  of 
C-C chemokines upon polyclonal activation (12).  It is not 
known  whether  the  production  of C-C  chemokines  by 
EU helper T  cells is part of an antigen-driven immune re- 
sponse or is under the control of other factors. 
Here, we present findings from a cohort of heterosexual 
couples in which  one partner was  HIV infected and  the 
other remained persistently uninfected despite having en- 
gaged in unprotected sexual intercourse (EU partner). The 
aim of the study was to identify immune mechanisms of re- 
sistance  to infection, possibly involving the  C-C  chemo- 
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type  CCR-5  allele.  We  identified  HIV  gp120-specific 
CD4 + T  cell clones, which were highly represented in the 
helper  cell population  of EU  partners,  and  assessed their 
ability to produce C-C  chemokines and suppress HIV rep- 
lication when stimulated with the specific antigen. 
Materials and Methods 
Study Population.  12  long-term sexually active heterosexual 
couples with discordant HIV serological status,  i.e., one partner 
was infected and seropositive and the other seronegative and un- 
infected (EU),  were enrolled in the study. At the time of entry 
into the study, and regularly thereafter, the infected partners were 
evaluated for laboratory (serum p24 antigen and CD4 cell count) 
and clinical parameters of HIV infection, and were assigned to a 
Centers for Disease Control (CDC) classification of disease stage. 
All CDC disease stages were represented with no preponderance 
of any one group. The EU partners were tested for HIV-1/2 an- 
tibodies, serum p24 antigen, and plasma HIV DNA (by PCR) at 
the time of entry into the study. Thereafter, they were monitored 
clinically and  tested for HIV-1/2  antibodies, p24  antigen,  and 
HIV DNA PCR (NASBA, Organon Teknika, Veedijk, Belgium) 
every 3 mo. Couples were followed for at least 24 too, and dur- 
ing that  time,  none  of the  EU  seronegative partners serocon- 
verted or showed any clinical or laboratory evidence of HIV in- 
fection. 
CCR-5 Genotyping.  A portion of  the CCR5 gene was ampli- 
fied by PCR from PBMC genomic DNA. The following primers 
were used: primer 1, 5' GTC TTC ATT ACA CCT GCA GCT 
C  3'; primer 2, 5' GTG AAG ATA AGC CTC ACA GCC 3'. 
PCR was conducted with I  p.g ofgenomic DNA using 0.2 mM 
dNTPs, 0.2 I~M primers, and 1.25  U  of AmpliTAq Gold poly- 
merase  (PE  Applied Biosystems, Branchburg,  NJ)  for 35  cycles 
(94°C for 40 s; 60°C for 40 s; 72°C for 40 s) after an initial 10- 
min denaturation at 94°C. The resulting PCR products were sep- 
arated on a 2% nusieve agarose gel. 
Limiting Dilution Assays.  Serial dilutions of PBMC  from EU 
and control uninfected unexposed individuals were plated in 48 
replicate microweUs in the presence of 5  ×  104 ~-irradiated au- 
tologous PBMC pulsed with 50 txg/ml of the C5 peptide. Cell 
proliferation was tested 8 d later by [3H]thymidine incorporation. 
The precursor frequency, i.e., the average number of cells needed 
to generate a single clone, was determined by plotting the num- 
ber of cells plated per well against the percent-negative wells (17). 
Generation and Characterization of EU T Cell Clones.  T  cell  lines 
were generated from freshly isolated PBMC after a single round of in 
vitro stimulation with the peptide and then cloned by limiting di- 
lution in the presence of allogeneic "/-irradiated PBMC, PHA, and 
hrlL-2 (Proleukin, Chiron B.V., Amsterdam, Netherlands). Clones 
exhibiting peptide-specific proliferative activity were maintained 
in culture by monthly restimulation with PHA and irradiated al- 
logeneic PBMC.  Fine mapping of epitopes recognized by the T 
cell clones was performed using autologous EBV-transformed B 
cell lines (EBV-B) incubated with a panel of synthetic peptides 
overlapping by one amino acid. For cytofluorimetric analysis, T 
cell clones (2 ×  105/sample) were stained with V[3-specific mono- 
clonal antibodies (PharMingen,  San  Diego,  CA;  Immunotech, 
Marseille, France)  for  30  rain  at  4°C,  washed  twice,  and  sus- 
pended in PBS. The cells were analyzed in a FACScan  ® (Becton 
Dickinson, Mountain View, CA). 
PCR Amplification and Sequencing of TCR cDNA.  Total  RNA 
was extracted from T  cell clones and used for first-strand cDNA 
synthesis using an oligo (dT)  primer and MMLV reverse tran- 
scriptase (GIBCO BRL, Gaithersburg, MD). 1/60 of each cDNA 
sample was amplified using the Vet-Cet- or V]3-C[3-specific oil- 
gonucleotides  previously  described  (18).  To  characterize  the 
N-region sequence of the V[~ chain, the remaining PCR ampli- 
fied product was subsequently run on a 12% native PAGE. DNA 
bands with similar migration properties were excised and eluted 
from the gel. DNA was subsequently precipitated and sequenced. 
Virus Isolation and Characterization.  Viruses were isolated from 
PBMC  of HIV infected patients by co-cultivation with PHA- 
stimulated PBMC  from  two  healthy donors  as  previously de- 
scribed (19).  In brief,  2  ×  106  patient PBMC  were  cultivated 
with  15  ×  106  donor  PBMC  in  RPMl-1640  (GIBCO  BRL) 
containing 10 U/ml rhlL-2, 10% FCS, glutamine, and antibiotics 
(IL-2 medium).  Cultures were followed until three consecutive 
positive determinations of HIV-1 p24 antigen were obtained. To 
prepare virus stock, 30  ×  106 donor PBMC were infected with 
p24 Ag-positive supernatant. After 7 d, supernatant was collected, 
centrifuged,  aliquoted,  and  frozen  at  -80°C.  Primary  viruses 
were characterized as SI or NSI by differential growth on MT2 or 
Jurkat-tat ceils. 
Virus Inhibition Assays with Supernatants  fiom EU Clones.  Super- 
natants  (75  ~I) of CD4  clones collected after 48-h  stimulation 
with PHA in the presence ofautologous B-LCL ceils were added 
to triplicate wells of PHA-activated healthy donor PBMC  (105 
cells/weU in 75 V,1 IL-2 medium) that had been inoculated with 
75 ~1 of serially diluted virus. After incubation overnight at 37°C, 
plates were washed by centrifugation and fresh IL-2 medium was 
added, with or without a  1:3  dilution of supernatant. Washing 
and readdition of medium was repeated after 2 d. At days 7 and 
11, p24 Ag was measured by ELISA. Virus lDs0 was newly deter- 
mined for each experiment and virus inhibition measured using 
the virus dilution giving a  TCID50  >10.  Neutralization of the 
EU clone suppressive activity by antichemokine antibodies was 
obtained by preincubating clone supernatants with a mixture of 
anti-RANTES (50  I.Lg/ml), anti-MIP-lc~ (30  p,g/ml), and anti- 
MIP-I~ (30 ~g/rnl) goat IgG (R&D Sys. Inc., Mineapolis, MN) 
for 30 rain at room temperature and adding the supematants to 
cultures of control PBMC inoculated with a NSI primary isolate 
(HIV-143). The purified IgG fraction from a nonimmune goat se- 
rum was used as control (110  wg/rul). Virus growth was moni- 
tored after 7-10 d by p24 Ag release. 
Results 
CCR-5 Genotypes.  PCR  amplification of genomic DNA 
corresponding to the 32-base pair deletion of CCR-5  was 
used to determine the CCR-5  genotype of the 12 EU part- 
ners. Eleven were homozygous for the wild-type CCR-5  al- 
lele,  one  was  CCR-5A32  heterozygous,  and  none  were 
CCR-5A32 homozygous (data not shown). 
HIVEnvelope-specific T  Cells.  HIV-specific T  cell responses 
in the EU partners were  detected using three HIV  gp120 
envelope peptides containing known  T  cell epitopes  (20) 
plus an additional peptide corresponding to  the fifth con- 
served  region  of  gp120  (peptide  C5).  Proliferative  re- 
sponses to the peptides were measured after a single round 
of stimulation of fresh PBMC.  Eighteen unexposed unin- 
fected (UU) subjects were used as controls. The C5 peptide 
stimulated 9  of 11  EU PBMC  tested but none  of the UU 
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Figure 1.  (a) Reactivity ofEU T cells to different HIV-1 gp120 pep- 
tides. PBMC from exposed uninfected (EU) partners (closed  symbols) and 
control unexposed uninfected (UU) individuals (open symbols) were cul- 
tured in RPMI medium supplemented with  5% human serum in the 
presence of 30 ~g/ml ofpeptide.  On day 7, cells were washed and then 
incubated for a further 5 d in fresh medium containing rlL-2 (20 U/ml). 
On day 12, 3 X 104 T cells were cultivated together with 10  s autologous 
irradiated PBMC in the presence of  the specific peptide and the prolifera- 
tive responses measured after 3 d by [3H]thymidine incorporation. The 
data are expressed as stimulation index (S.L). An individual was consid- 
ered positive when the S.I. was >2. The peptides used were derived from 
the  following HIV-11IIb sequence: peptide C1,  HEDIISLWDQSLK- 
PCVKLT; peptide V3, RIHIGPGRAFYTTKN;  peptide C4, KQFINM- 
WQEWGKAMYA; peptide C5, SELYKYKWKIEPLGVAPTKAKRR. 
The sequence of the control peptide was TPSLLEQEVKPSTELEYLGP- 
DEND. (b) Frequency ofgpl20-C5 specific T cells in EU partners. (Left) 
A representative experiment with PBMC from one EU and one control 
UU individual. (Right) Individual frequencies of C5-specific T cells from 
EU and UU PBMC. 
PBMC,  whereas  the  other  three  peptides  had  no  activity 
except for the V3 peptide, which stimulated one EU PBMC 
and one UU PBMC (Fig.  1 a).  These results indicated that 
the  T  cell repertoire  of EU but not UU  individuals  con- 
tains  a  high  number  of gp120-C5-specific  T  cells.  To 
quantify  more  precisely  the  differences  between  EU  and 
UU  individuals  we performed limiting dilution analysis of 
EU  and  UU  peripheral  T  lymphocytes upon  stimulation 
with the C5 peptide.  As shown in Fig.  1 b, the mean fre- 
quency of C5-specific EU T  cells was significantly higher 
(P <0.001) than that ofUU  T  cells (1 in 7,700 -+ 4,700 for 
EU versus  1 in  18,000  -+ 6,500 for UU).  The C5 peptide 
was therefore selected for further analysis. 
Generation and  Characterization of CD4  T  Cell  Clones. 
CS-specific T  cells from four EU partners,  including three 
CCR-5  homozygous  (EU23,  EU26,  EU28)  and  one 
CCR-5fi32 heterozygous (EU25), were cloned under lim- 
iting dilution conditions, and each of the clones character- 
ized.  All clones generated were CD4+/CD8 -.  The TCR 
V[3 genes  usage was  determined  by flow cytometry using 
Table 1.  TCR Genes of GP120-C5-specific CD4 Clones 
from Exposed Uninfected Individuals 
TCK 
Donor  Clone  V[3  N-D-N  J[3  Vet 
EU 23 
EU 25 
EU 26 
EU 28 
EU23-08 V~5.2  TTGAGGGGTGTAGAC  J~1.5  Vex9 
EU23-09 V~5.2  TTGAGGGGTGTAGAC  J~1.5  V(~9 
EU23-20 V~5.2  TTGAGGGGTGTAGAC  J~1.5  Vtx9 
EU25-01  V[36  CCGGGTGGG  JI32.1 
EU25-02 V[33  TCGAAGGTCACG  J[32.1 
EU25-03 V[33  TCGAAGGTCACG  J~2.1 
EU25-04 V[33  TCGAAGGTCACG  J[32.1 
EU25-06 V[33  TCGAAGGTCACG  J[32.1 
EU25-13 V[33  TCGAAGGTCACG  J[32.1 
EU26-02 V~17  ATAGGGCTAGCGGGT  J~2.2  V~17 
EU26-03 V~I7  ATAGGGCTAGCGGGT  J~2.2 
EU26-05 V~17  ATAGGGCTAGCGGGT  J~2.2 
EU26-11 V~17  ATAGGGCTAGCGGGT  J~;2.2  Vot17 
EU26-18 V~17  ATAGGGCTAGCGGGT  J~;2.2  V(x17 
EU26-45 V~17  ATAGGGCTAGCGGGT  J~2.2  V(x17 
EU26-50 V~3  ND  ND  ND 
EU28-01 V~7.1  ACCAGGGGACCTTGGT J~2.7 
EU28-04 V~7.1  ACCAGGGGACCTTGGT J~2.7 
specific  monoclonal  antibodies  and  by  oligonucleotide- 
directed  PC1L  amplification  of cDNA  of the  V[3-D-J[3 
junctional  region  and  Ve~  genes.  Table  1  lists  the  TCR 
genes  expressed  by  each  of the  clones.  This  analysis  re- 
vealed  that  the  majority  of clones  derived  independently 
from each EU partner expressed the same TCR as if they 
were derived from the expansion of a single precursor. The 
presence of an oligoclonal response in the four EU partners 
from  which  the  clones  were  derived,  together  with  the 
high number ofC5-specific T  cells detected in the majority 
of EU partners tested,  suggested that the C5 peptide  con- 
tains one or more dominant epitopes recognized by EU T 
cells.  All EU clones were then tested on a panel of 12-resi- 
due  synthetic peptides  representing  the  C5  region.  Three 
epitopes, YKVVKIEPLGVAPT, LGVAPTKAKRRV, and 
IEPLGVAPTKAK, were identified (data not shown). 
Antigen-driven  C-C  Chemokine Production by  EU  Clones. 
The availability of CD4 clones specific for an HIV peptide 
allowed  us  to  ask  the  question  of whether  such  clones, 
upon recognition of the specific antigen presented by self- 
antigen-presenting  cells,  were  capable of producing HIV- 
suppressive  C-C  chemokines.  Stimulation  of EU  clones 
with  the  specific peptide  or with  PHA,  but  not with  the 
control peptide,  induced the release of high amounts of all 
three C-C  chemokines (16  -+ 5.6 ng/ml R_ANTES, 67  -+ 
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Figure 2.  (a) Antigen driven release ofC-C chemokines  by EU clones. 
Peptide C5-specific clones from exposed uninfected (EU) partners (106 
ceUs/ml) were cultivated with autologous B-LCL cells (5 X 105/ml) in 
the presence of 30 txg/ml of the C5 peptide (closed bars), PHA (dashed 
bars), or an unrelated control peptide (open bars). Supematants were col- 
lected after 48 h and tested for the presence of RANTES, MIP-lcx, and 
MIP-I[3 using commercially available ELISA (R&D  Systems). Clones 
from unexposed uninfected individuals (UU) were stimulated under the 
same conditions in the presence of PHA or control peptide only. (b) EU 
clones suppress HIV-1 NSI primary isolates. Supematants of EU clones 
collected after 48-h stimulation with PHA in the presence of autologous 
B-LCL cells were added to cultures of  PBMC from UU subjects that had 
been inoculated with two HIV-1 NSI primary isolates, HIV-140 (open 
bars), HIV-143 (closed bars). Results are expressed as percent suppression of 
p24 Ag production.  (c)  Anti-C-C chemokine antibodies abrogate the 
suppressive activity of  EU clones. Growth ofa NSI primary isolate (HIV- 
143 )  on  control  PBMCs in  the  presence of supematant from  clone 
EU23.9, which was pretreated with a mixture of0~-RANTES,  o~-MIP-Ic~, 
and Ix-MIP-l[3  antibodies or control goat IgG. 
36 ng/ml MIP-le~, and 61  +  18 ng/ml MIP-1IB). In con- 
trast,  PHA stimulation  of the  UU  clones  failed to induce 
production of the three chemokines as efficiently (4  +  2.3 
ng/ml RANTES,  19  +  17 ng/ml MIP-10~,  and  14  _+  12 
ng/ml  MIP-I[~)  (Fig.  2  a).  Comparison  of the  levels  of 
the  three  C-C  chemokines  produced  under  polyclonal 
versus antigen-specific activation revealed that induction of 
R_ANTES production by antigen-specific and PHA stimu- 
lation was similar in the majority of clones tested,  whereas, 
for MIP-lo~  and  MIP-I~,  PHA stimulation  generally  in- 
duced higher levels.  In all cases, however, the levels of the 
three chemokines were substantially higher than those pre- 
viously reported (10) for CD4 clones. 
HIV- 1 Inhibitory Aaivity of EU Clones.  Next,  we investi- 
gated the  ability  of the  C5-specific EU clones to suppress 
HIV infection in vitro.  Supernatants from PHA-stimulated 
EU  and  UU  clones  were  added  to  cultures  of control 
PBMC inoculated with two HIV-1 NSI (HIV-140, HIV-143  ) 
and two HIV-1 SI (HIV-14s, HIV-14s  ) primary isolates. All 
six EU clones tested potently suppressed the two NSI iso- 
lates  (Fig. 2  b),  but showed no activity on the two SI iso- 
lates  (data  not shown).  In contrast,  three  of the  four UU 
clones failed to suppress all isolates tested but instead signif- 
icantly enhanced replication of the two NSI isolates (Fig. 2 
b).  One  UU  clone  (UU-KT02)  displayed  a  level  of sup- 
pressive activity toward the two NSI isolates similar to that 
of EU clones. 
The  selectivity  of the  suppressive  activity  of the  EU 
clones  for the  NSI  isolates  suggested  that  in  this  experi- 
mental system,  C-C  chemokines were the major suppres- 
sive factor. To exclude the role of other suppressive factors, 
the  cell-free  culture  supernatants  of the  EU  clones  were 
pretreated with a mixture of neutralizing antibodies against 
RANTES,  MIP-loe,  and  MIP-1B  before  measuring  the 
suppressive  activity  against  the  NSI  isolate  HIV-143.  As 
shown  in  Fig.  2  c,  the  anti-chemokine  antibodies  com- 
pletely abrogated the suppressive activity, whereas no effect 
was  observed with  the  control  antibodies,  indicating  that 
C-C  chemokines are the major, if not the only, HIV sup- 
pressive factor released by EU CD4 clones. 
Discussion 
These data are evidence that,  upon antigen stimulation, 
HIV-specific helper T  cells can produce C-C  chemokines 
that  suppress  infection  by  CCR-5-dependent  HIV-1  vi- 
ruses.  In vitro,  such HIV-suppressive  activity requires  the 
production  of relatively  high  levels  of C-C  chemokines, 
because clones that produce low levels of C-C chemokines 
have the opposite effect on HIV rephcation, i.e.,  enhance- 
ment.  The enhancing effect may be due to the production 
of  other  factors,  including  cytokines,  which  upregulate 
HIV replication.  The previous observation that CD4 clones 
from EU individuals produce higher levels of C-C  chemo- 
kines than clones from control unexposed individuals  (12) 
was confirmed by our study.  This was also associated with 
the  expression  of potent  HIV-suppressive  activity specific 
for NSI isolates.  However, suppressive activity could also be 
detected in one UU clone (UU-KT02) that produced only 
limited  quantities  of C-C  chemokines.  Thus,  lack  of en- 
hancing cytokine production may have resulted in potenti- 
ation of the HIV-suppressive activity of C-C chemokines. 
One  could predict  that  protection  against  sexual  trans- 
mission  depends  on  the  balance  between  enhancing  and 
suppressive  activity  resulting  from  either  the  number  of 
HIV-specific T  cells producing suppressive  chemokines or 
extra  production  at  the  single  cell  level.  It  is  not  clear 
which factors deten'nine an increase in the number of clones 
producing higher  levels  of C-C  chemokines  seen  in  EU 
individuals. A  high number of C-C chemokine-producing 
cells may be the result of an immune response maintained 
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in  each  EU  partner  of a  large  number  of clones  bearing 
identical T  cell receptors specific for the C5 env region sug- 
gests a critical role of this region in inducing protective re- 
sponses to  HIV.  On  the  other hand,  numerous  reports of 
robust  Thl  type  responses  in  EU  individuals  (1)  suggest 
that Thl  cytokines might upregulate C-C  chemokine pro- 
duction. Thus, some mechanism of control of C-C  chemo- 
kine production by other ceUs of the immune system may 
be upregulated in EU individuals. 
Significant differences in the levels of C-C  chemokines 
produced by EU versus UU  clones were also detected after 
polyclonal activation. EU individuals may therefore repre- 
sent a population with a genetic predisposition to high pro- 
duction of C-C  chemokines, which may help in generat- 
ing  HIV-suppressive  responses  upon  the  first  encounter 
with HIV antigens. An immune-mediated mechanism and 
genetic predisposition to high C-C  chemokine production 
are not necessarily mutually exclusive, and indeed might be 
synergistic. For vaccine design, it will be important to un- 
derstand  to  what  extent  genetic  predisposition favors  the 
generation  of  C-C  chemokine-mediated  protective  re- 
sponses  and  whether  an  immune  manipulation  targeted 
against particular HIV antigens could enhance C-C  chemo- 
kine production to a level sufficient to prevent sexual trans- 
mission. 
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